Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia

European Journal of Pharmacology

Volumn 664, Issue 1-3, 2011, Pages 45-53

  Robich, Michael P ^a,b,c   Osipov, Robert M ^b   Chu, Louis M ^a   Han, Yuchi ^b   Feng, Jun ^c   Nezafat, Reza ^b   Clements, Richard T ^c   Manning, Warren J ^b   Sellke, Frank W ^a,c  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Glucose metabolism; Metabolic syndrome; Myocardial infarction risk factor modification; Myocardial ischemia; Resveratrol

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; INSULIN RECEPTOR SUBSTRATE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESVERATROL; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CARDIOVASCULAR MAGNETIC RESONANCE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; DIET SUPPLEMENTATION; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; INTRACELLULAR SIGNALING; INTRAVENOUS GLUCOSE TOLERANCE TEST; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SWINE; TREATMENT DURATION;

ANIMALS; BIOLOGICAL MARKERS; CHOLESTEROL; CORONARY ARTERY DISEASE; DIET; DIETARY SUPPLEMENTS; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; HEART; INFLAMMATION; INSULIN; MAGNETIC RESONANCE IMAGING; METABOLIC SYNDROME X; MICROVESSELS; MUSCLE CELLS; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; PROTEIN TRANSPORT; RISK FACTORS; STILBENES; SWINE;

EID: 79957895283     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.059     Document Type: Article

References (34)

1. Barouch, L.A., Berkowitz, D.E., Harrison, R.W., O'Donnell, C.P., Hare, J.M., 2003. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108, 754-759. (Pubitemid 36999263)
2. Barsotti, A., Giannoni, A., Di Napoli, P., Emdin, M., 2009. Energy metabolism in the normal and in the diabetic heart. Curr. Pharm. Des. 15, 836-840.
3. Bordone, L., Guarente, L., 2007. Sirtuins and beta-cell function. Diabetes Obes. Metab. 9 (Suppl 2), 23-27.
4. Boudina, S., Abel, E.D., 2007. Diabetic cardiomyopathy revisited. Circulation 115, 3213-3223. (Pubitemid 47012236)
5. Chen, W., Silver, D.L., Smith, J.D., Tall, A.R., 2000. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages. J. Biol. Chem. 275, 30794-30800.
6. Dolinsky, V.W., Chan, A.Y.M., Robillard Frayne, I., Light, P.E., Des Rosiers, C., Dyck, J.R.B., 2009. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119, 1643-1652.
7. Elliott, P.J., Jirousek, M., 2008. Sirtuins: novel targets for metabolic disease. Curr. Opin. Investig. Drugs 9, 371-378.
8. Fujii, N., Jessen, N., Goodyear, L.J., 2006. AMP-activated protein kinase and the regulation of glucose transport. Am. J. Physiol. Endocrinol. Metab. 291, E867-E877.
9. Gracia-Sancho, J., Villarreal Jr., G., Zhang, Y., Garcia-Cardena, G., 2010. Activation of SIRT1 by resveratrol induces KLF2 expression conferring an endothelial vasoprotective phenotype. Cardiovasc Res 85, 514-519.
10. Graham, T.E., Yang, Q., Bluher, M., Hammarstedt, A., Ciaraldi, T.P., Henry, R.R., Wason, C.J., Oberbach, A., Jansson, P.A., Smith, U., Kahn, B.B., 2006. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354, 2552-2563.
11. Hung, L.M., Chen, J.K., Huang, S.S., Lee, R.S., Su, M.J., 2000. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res. 47, 549-555.
12. Illingworth, D.R., Bacon, S., 1987. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. Am. J. Cardiol. 60, 33G-42G.
13. Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M.B., Thompson, S.G., Collins, R., Danesh, J., 2010. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375, 132-140.
14. Kaur, G., Rao, L.V., Agrawal, A., Pendurthi, U.R., 2007. Effect of wine phenolics on cytokine-induced C-reactive protein expression. J. Thromb. Haemost. 5, 1309-1317.
15. Kim, R.J., Fieno, D.S., Parrish, T.B., Harris, K., Chen, E.L., Simonetti, O., Bundy, J., Finn, J.P., Klocke, F.J., Judd, R.M., 1999. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100, 1992-2002. (Pubitemid 29529292)
16. Lavu, S., Boss, O., Elliott, P.J., Lambert, P.D., 2008. Sirtuins - novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 7, 841-853.
17. Liu, Y., Thornton, J.D., Cohen, M.V., Downey, J.M., Schaffer, S.W., 1993. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88, 1273-1278. (Pubitemid 23264048)
18. Mattagajasingh, I., Kim, C.S., Naqvi, A., Yamamori, T., Hoffman, T.A., Jung, S.B., DeRicco, J., Kasuno, K., Irani, K., 2007. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U S A 104, 14855-14860.
19. Milani, R.V., Lavie, C.J., 2003. Prevalence and profile of metabolic syndrome in patients following acute coronary events and effects of therapeutic lifestyle change with cardiac rehabilitation. Am. J. Cardiol. 92, 50-54.
20. Miranda, P.J., DeFronzo, R.A., Califf, R.M., Guyton, J.R., 2005. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am. Heart J. 149, 33-45.
21. Muoio, D.M., Newgard, C.B., 2005. Metabolism: A is for adipokine. Nature 436, 337-338. (Pubitemid 41059036)
22. Panza, J.A., Casino, P.R., Kilcoyne, C.M., Quyyumi, A.A., 1993. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 87, 1468-1474. (Pubitemid 23133089)
23. Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., Leid, M., McBurney, M.W., Guarente, L., 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429, 771-776. (Pubitemid 38833129)
24. Plenge, J.K., Hernandez, T.L., Weil, K.M., Poirier, P., Grunwald, G.K., Marcovina, S.M., Eckel, R.H., 2002. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106, 1447-1452.
25. Robich, M.P., Chu, L.M., Chaudray, M., Nezafat, R., Han, Y., Clements, R.T., Laham, R.J., Manning, W.J., Coady, M.A., Sellke, F.W., 2010a. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 148, 453-462.
26. Robich, M.P., Osipov, R.M., Nezafat, R., Feng, J., Clements, R.T., Bianchi, C., Boodhwani, M., Coady, M.A., Laham, R.J., Sellke, F.W., 2010b. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 122, S142-S149.
27. Rodgers, J.T., Puigserver, P., 2007. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc. Natl. Acad. Sci. U S A 104, 12861-12866.
28. Shah, A., Rader, D.J., Millar, J.S., 2010. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis 210 (1), 35-40.
29. Stanley, W.C., Lopaschuk, G.D., McCormack, J.G., 1997. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 34, 25-33.
30. Vidavalur, R., Otani, H., Singal, P.K., Maulik, N., 2006. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp. Clin. Cardiol. 11, 217-225.
31. Walle, T., Hsieh, F., DeLegge, M.H., Oatis Jr., J.E., Walle, U.K., 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377-1382.
32. Wang, C.Y., Kim, H.H., Hiroi, Y., Sawada, N., Salomone, S., Benjamin, L.E., Walsh, K., Moskowitz, M.A., Liao, J.K., 2009. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci. Signal 2, ra11.
33. Weisova, P., Concannon, C.G., Devocelle, M., Prehn, J.H., Ward, M.W., 2009. Regulation of glucose transporter 3 surface expression by the AMP-activated protein kinase mediates tolerance to glutamate excitation in neurons. J. Neurosci. 29, 2997-3008.
34. Yoshizaki, T., Milne, J.C., Imamura, T., Schenk, S., Sonoda, N., Babendure, J.L., Lu, J.C., Smith, J.J., Jirousek, M.R., Olefsky, J.M., 2009. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 29, 1363-1374.